209 related articles for article (PubMed ID: 31918218)
1. The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer.
Yang C; Tu K; Gao H; Zhang L; Sun Y; Yang T; Kong L; Ouyang D; Zhang Z
Biomaterials; 2020 Feb; 232():119751. PubMed ID: 31918218
[TBL] [Abstract][Full Text] [Related]
2. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
3. Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer.
Zhang C; Zhu J; Yuan X; Yan Z; Ye H; Xiong T; Xu A; Li C; Ji D; Yang S; Zhang J; Zhang Y; Wu J; Huang Z
J Med Chem; 2024 Jan; 67(1):479-491. PubMed ID: 38110353
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
5. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
6. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
7. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
[TBL] [Abstract][Full Text] [Related]
8. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
9. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.
Cao Y; Ge X; Zhu X; Han Y; Wang P; Akakuru OU; Wu A; Li J
Adv Sci (Weinh); 2023 Jul; 10(21):e2300545. PubMed ID: 37147783
[TBL] [Abstract][Full Text] [Related]
10. Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy.
Date T; Kuche K; Chaudhari D; Ghadi R; Sahel DK; Chitkara D; Jain S
ACS Biomater Sci Eng; 2022 Jun; 8(6):2349-2362. PubMed ID: 35522530
[TBL] [Abstract][Full Text] [Related]
11. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
13. Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum
Muhammad N; Cai-Ping T; Nasreen S; Mao ZW
Chem Asian J; 2021 Aug; 16(16):2276-2279. PubMed ID: 34231967
[TBL] [Abstract][Full Text] [Related]
14. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
15. Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer.
Paul M; Ghosh B; Biswas S
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128281. PubMed ID: 37992920
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable and pH-Responsive Acetalated Dextran (Ac-Dex) Nanoparticles for NIR Imaging and Controlled Delivery of a Platinum-Based Prodrug into Cancer Cells.
Braga CB; Perli G; Becher TB; Ornelas C
Mol Pharm; 2019 May; 16(5):2083-2094. PubMed ID: 30901218
[TBL] [Abstract][Full Text] [Related]
17. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
18. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
[TBL] [Abstract][Full Text] [Related]
19. A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance .
Liu Y; Wang D; Liu H; Liu L; Li S; Zhou Z; Lu L; Liu X; He L; He D; Yu CY; Wei H
J Med Chem; 2023 Mar; 66(6):4045-4058. PubMed ID: 36897884
[TBL] [Abstract][Full Text] [Related]
20. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
